Literature DB >> 20329730

Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors.

Keduo Qian1, Reen-Yun Kuo, Chin-Ho Chen, Li Huang, Susan L Morris-Natschke, Kuo-Hsiung Lee.   

Abstract

In our continuing study of triterpene derivatives as potent anti-HIV agents, different C-3 conformationally restricted betulinic acid (BA, 1) derivatives were designed and synthesized in order to explore the conformational space of the C-3 pharmacophore. 3-O-Monomethylsuccinyl-betulinic acid (MSB) analogues were also designed to better understand the contribution of the C-3' dimethyl group of bevirimat (2), the first-in-class HIV maturation inhibitor, which is currently in phase IIb clinical trials. In addition, another triterpene skeleton, moronic acid (MA, 3), was also employed to study the influence of the backbone and the C-3 modification toward the anti-HIV activity of this compound class. This study enabled us to better understand the structure-activity relationships (SAR) of triterpene-derived anti-HIV agents and led to the design and synthesis of compound 12 (EC(50): 0.0006 microM), which displayed slightly better activity than 2 as a HIV-1 maturation inhibitor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20329730      PMCID: PMC2860721          DOI: 10.1021/jm901782m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

1.  Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel.

Authors:  S A Wegner; S K Brodine; J R Mascola; S A Tasker; R A Shaffer; M J Starkey; A Barile; G J Martin; N Aronson; W W Emmons; K Stephan; S Bloor; J Vingerhoets; K Hertogs; B Larder
Journal:  AIDS       Date:  2000-05-26       Impact factor: 4.177

Review 2.  Current strategies and limitations of HIV vaccines.

Authors:  Omkar U Kawalekar; Devon J Shedlock; David B Weiner
Journal:  Curr Opin Investig Drugs       Date:  2010-02

Review 3.  Anti-HIV drug development--an overview.

Authors:  Candida F Pereira; Judith T M L Paridaen
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

4.  Drug interactions in patients infected with human immunodeficiency virus.

Authors:  S C Piscitelli; C Flexner; J R Minor; M A Polis; H Masur
Journal:  Clin Infect Dis       Date:  1996-10       Impact factor: 9.079

Review 5.  The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV.

Authors:  Donglei Yu; Carl T Wild; David E Martin; Susan L Morris-Natschke; Chin-Ho Chen; Graham P Allaway; Kuo-Hsiung Lee
Journal:  Expert Opin Investig Drugs       Date:  2005-06       Impact factor: 6.206

6.  HIV-1 drug resistance in newly infected individuals.

Authors:  D Boden; A Hurley; L Zhang; Y Cao; Y Guo; E Jones; J Tsay; J Ip; C Farthing; K Limoli; N Parkin; M Markowitz
Journal:  JAMA       Date:  1999 Sep 22-29       Impact factor: 56.272

7.  Total synthesis of (-)-kaitocephalin.

Authors:  Masanori Kawasaki; Tetsuro Shinada; Makoto Hamada; Yasufumi Ohfune
Journal:  Org Lett       Date:  2005-09-15       Impact factor: 6.005

8.  Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers.

Authors:  David E Martin; Robert Blum; John Wilton; Judy Doto; Hal Galbraith; Gina L Burgess; Philip C Smith; Charles Ballow
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

9.  Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.

Authors:  David E Martin; Robert Blum; Judy Doto; Hal Galbraith; Charles Ballow
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.

Authors:  Patrick F Smith; Abayomi Ogundele; Alan Forrest; John Wilton; Karl Salzwedel; Judy Doto; Graham P Allaway; David E Martin
Journal:  Antimicrob Agents Chemother       Date:  2007-07-16       Impact factor: 5.191

View more
  21 in total

1.  Resistance to Second-Generation HIV-1 Maturation Inhibitors.

Authors:  Emiko Urano; Uddhav Timilsina; Justin A Kaplan; Sherimay Ablan; Dibya Ghimire; Phuong Pham; Nishani Kuruppu; Rebecca Mandt; Stewart R Durell; Theodore J Nitz; David E Martin; Carl T Wild; Ritu Gaur; Eric O Freed
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

2.  Conjugates of betulin derivatives with AZT as potent anti-HIV agents.

Authors:  Juan Xiong; Yoshiki Kashiwada; Chin-Ho Chen; Keduo Qian; Susan L Morris-Natschke; Kuo-Hsiung Lee; Yoshihisa Takaishi
Journal:  Bioorg Med Chem       Date:  2010-07-07       Impact factor: 3.641

3.  Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors.

Authors:  Keduo Qian; Ibrahim D Bori; Chin-Ho Chen; Li Huang; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2012-09-14       Impact factor: 7.446

Review 4.  Recent advances in natural anti-HIV triterpenoids and analogs.

Authors:  Hai-Feng Wu; Susan L Morris-Natschke; Xu-Dong Xu; Mei-Hua Yang; Yung-Yi Cheng; Shi-Shan Yu; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2020-07-14       Impact factor: 12.944

5.  Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.

Authors:  Emiko Urano; Sherimay D Ablan; Rebecca Mandt; Gary T Pauly; Dina M Sigano; Joel P Schneider; David E Martin; Theodore J Nitz; Carl T Wild; Eric O Freed
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

6.  A-ring modified betulinic acid derivatives as potent cancer preventive agents.

Authors:  Hsin-Yi Hung; Kyoko Nakagawa-Goto; Harukuni Tokuda; Akira Iida; Nobutaka Suzuki; Ibrahim D Bori; Keduo Qian; Kuo-Hsiung Lee
Journal:  Bioorg Med Chem Lett       Date:  2013-12-16       Impact factor: 2.823

7.  Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid.

Authors:  Francesca Curreli; Hongtao Zhang; Xihui Zhang; Ilya Pyatkin; Zagorodnikov Victor; Andrea Altieri; Asim K Debnath
Journal:  Bioorg Med Chem       Date:  2010-11-25       Impact factor: 3.641

Review 8.  Structure and Anti-HIV Activity of Betulinic Acid Analogues.

Authors:  Qiu-Xia Huang; Hong-Fei Chen; Xing-Rui Luo; Yin-Xiang Zhang; Xu Yao; Xing Zheng
Journal:  Curr Med Sci       Date:  2018-06-22

9.  Fluorinated betulinic acid derivatives and evaluation of their anti-HIV activity.

Authors:  Jizhen Li; Masuo Goto; Xiaoming Yang; Susan L Morris-Natschke; Li Huang; Chin-Ho Chen; Kuo-Hsiung Lee
Journal:  Bioorg Med Chem Lett       Date:  2015-11-11       Impact factor: 2.823

Review 10.  Biotechnological production of betulinic acid and derivatives and their applications.

Authors:  Tianyue An; Wenlong Zha; Jiachen Zi
Journal:  Appl Microbiol Biotechnol       Date:  2020-02-28       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.